| An SI Board Since February 2010 |
| Posts |
SubjectMarks |
Bans |
Symbol |
| 6 |
2 |
0
|
CYCC |
|
Cyclacel (CYCC) is a minicap ($60M) biotech development company with 3 principal drugs in development for significant indications:
SELICICLIB, a CDK inhibitor in phase 2 trials for Non Small Cell Lung Cancer and nasopharyngeal cancer;
SAPACITABINE, in phase 2 for NSCLC, AML and myelodysplastic syndrome
CY116, in phase 1 for solid tumors.
CYCC rocketed in early January 2010 on publication of an article reporting that Seliciclib was effective against cancer cell lines that are resistant to other drugs that target EGF receptors. It got another boost in February on publication that Seliciclib “can” reverse resistance to Femara in Breast cancer.
CYCC has virtually no revenues and must go regularly to capital markets to raise cash. Dilution will be a fact of life. Though it has been reducing expenses, it has roughly a year’s worth of cash burn on hand. It is also in continual danger of delisting for falling below the Nasdaq $50M market cap threshold. And it is the target of (subsequently proven to be unfounded) rumors that it is about to be taken over at a premium.
Just reread that intro and I may have been too negative. I should have bolded significant indications. The payoff could be huge, but on a day to day basis be wary of unexplained runups. Up to now the mantra has been - sell 'em.
|
|
|
